ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Latest Government Action





















R&D Insight
Can you help?
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
Dame Sally Davies Tweet
Assessing antibiotic value: DTR, fire extinguishers, and a view from Australia
News from Davos 2020: Some positive signs, but overall a fragile antibiotic market at a tipping point
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
Limits on measuring the impact of rapid antimicrobial susceptibility testing (AST)
DTR Gram-negative infections: Are new antibiotics making a difference?
Lancet: 10-20-30 targets to address AMR by 2030
Developing systemic & inhaled antibiotics for lung infections
Melinta goes bankrupt / Never let a good crisis go to waste
FDA workshop: Insights on inhaled antifungals and antibacterials
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
Modeling the value of an effective antibiotic — Megiddo et al.
FDA Workshop: Animal Models To Support Antibacterial Development (5 Mar 2020, post-meeting notes)
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
Alexander Fleming Tweet
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
U.S. Senator Michael Bennet Tweet